Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

23andMe

Biotech & Life Sciences · Sunnyvale, United States · Founded 2006 Unicorn

Helping people access, understand, and benefit from the human genome

Valuation
$150M
Market cap · 2026
Revenue
$190M
Latest reported FY

Investors

18 investors on 23andMe's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Genentech
Mohr Davidow Ventures
Stephens Investment Management
NEA
Alphabet | Google
Series B+ 13 investors entered at this stage
Xfund
Future Planet Capital
GSK
Illumina
Sergey Brin
Anne Wojcicki
NewView Capital
Casdin Capital
Yuri Milner
MPM BioImpact
Johnson & Johnson Development Corporation
Fidelity Investments
Sequoia

Global footprint

Where 23andMe has talent and traffic

AI talent share
2.5% of workforce is AI talent
(14 of 560 staff)
Core AI40.71%
Other AI101.79%
Non-AI workforce54697.5%
Workforce by country
13 countries with
team presence
🇺🇸 United States95.3%
🇨🇳 China0.8%
🇧🇩 Bangladesh0.4%
🇧🇷 Brazil0.4%
🇦🇷 Argentina0.4%
Top 5 of 13 shown
Web traffic by country
4.8M monthly visits
across markets
🇺🇸 United States76.1%
🇬🇧 United Kingdom6.1%
🇨🇦 Canada5.7%
🇦🇺 Australia0.5%
🇻🇳 Vietnam0.5%
Top 5 markets shown

Patent intelligence

$52M patent portfolio · 50 active families

Estimated portfolio value
$52M
34.4% of market cap · 9.7× smaller than top peer Insulet ($502M)
50 active patent families
Where 23andMe innovates Data miningData scienceComputational biologySoftwareBioinformatics

Where 23andMe concentrates vs peers

Each axis is a top-10 topic across 23andMe and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

23andMe's 4 investments and acquisitions.

Every disclosed deal where 23andMe appeared as a backer or acquirer, 2012–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across 23andMe's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where 23andMe deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        23andMe's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about 23andMe

        An AI-synthesized read of the highest-engagement posts about 23andMe on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See 23andMe on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.